IBD:克罗恩病患者中一个遗传变异与手术后疾病复发密切相关

2021-11-21 MedSci原创 MedSci原创

克罗恩病:一种消化道的慢性、反复发作和非特异性的透壁性炎症, 病变呈节段性分布, 可累及消化道任何部位,其中以末端回肠最为常见,结肠和肛门病变也较多。

      克罗恩病是一种会引起胃肠道任何部位的慢性炎症。有研究显示,在被确诊时,有40% 的患者有回结肠疾病,30%的患者有小肠疾病,30%的患者有结肠疾病。CD 的位置在整个临床过程中相对稳定,有 15% 的患者在诊断 10 年后可能会发生疾病位置的变化。然而,疾病行为会随着时间发生显着变化。在超过 10 年的病程中,很大一部分最初表现为非狭窄性、非穿透性 CD 表型的患者进展为狭窄性 (27%) 或穿透性 (29%) 疾病。CD 相关并发症的治疗通常需要手术干预,70%–80% 的患者在临床过程中需要某种手术治疗。此外,发现手术后3年内CD复发率为 30%。

 

      早期研究表明CD相关易感性候选基因与狭窄回肠疾病与手术需要和NOD2基因变异之间存在关联。欧洲 IBDchip组织将NOD2基因确定为回肠艰难梭菌肠炎感染、回肠狭窄的主要影响遗传预测因子,至于NOD2在术后手术复发中的作用,最近的一项荟萃分析研究报告称,NOD2与手术复发无显着相关性(OR,1.58 [0.97–2.57];P = 0.06)。因此,遗传学对 CD 患者术后手术复发风险的作用仍有待阐明。本项研究旨在通过跨基因组的无假设搜索来确定临床和遗传风险因素模型,该模型可以预测 CD 患者首次腹部手术后的手术复发风险。

 

 

      为了进行研究验证,两项独立的炎症性肠病 (IBD) 队列研究用于推导和验证遗传风险概况。使用 Illumina Immunochip 定制基因分型阵列对研究对象进行基因分型。手术复发定义为在第一次腹部手术后进行了第二次或多次腹腔肠切除术;非手术复发被定义为在第一次腹部手术后没有进一步的腹部切除术。

 

      研究结果显示在研究入组时至少接受过1次腹部手术的372名CD患者中,132 名(35.5%)在第一次腹部手术后再次手术复发,240 名(64.5%)在随访结束时不需要进行后续腹部手术。在临床因素中,多变量分析显示免疫调节使用史( [OR],3.96;P=0.002)和CD首次手术较早(OR,1.12;P = 1.01E-04)是主要影响因素。基因型关联测试在TCF4的 chr18q21.2处鉴定了一个全基因组显着位点——rs2060886,与手术复发风险相关(OR,dom,4.10 [2.37–7.11];P = 4.58E-08)。

 

      本项研究证实TCF4中的新的基因突变位点rs2060886与 CD 患者第一次腹部手术后全基因组显着性水平的手术复发风险相关。CD 首次肠道手术的时间与较高的手术复发风险相关。这些结果表明,遗传变异可能有助于指导重复腹部手术风险最高的患者的 CD 管理策略。

原始出处:

Ming-Hsi Wang. Et al. Novel Genetic Variant Predicts Surgical Recurrence Risk in Crohn’s Disease Patients. Inflammatory Bowel Diseases.2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1798896, encodeId=ad011e988964a, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Thu Jun 23 05:02:13 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073998, encodeId=2afd10e39982a, content=还行。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b21989170, createdName=1e19ea9dm99(暂无匿称), createdTime=Thu Nov 25 22:12:14 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263683, encodeId=ef8812636833d, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342924, encodeId=f2cd13429242b, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377215, encodeId=9a0c13e7215e7, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072579, encodeId=37a310e257974, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe1f2374173, createdName=122fcb19m83暂无昵称, createdTime=Sun Nov 21 18:25:44 CST 2021, time=2021-11-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1798896, encodeId=ad011e988964a, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Thu Jun 23 05:02:13 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073998, encodeId=2afd10e39982a, content=还行。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b21989170, createdName=1e19ea9dm99(暂无匿称), createdTime=Thu Nov 25 22:12:14 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263683, encodeId=ef8812636833d, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342924, encodeId=f2cd13429242b, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377215, encodeId=9a0c13e7215e7, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072579, encodeId=37a310e257974, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe1f2374173, createdName=122fcb19m83暂无昵称, createdTime=Sun Nov 21 18:25:44 CST 2021, time=2021-11-21, status=1, ipAttribution=)]
    2021-11-25 1e19ea9dm99(暂无匿称)

    还行。。。。。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1798896, encodeId=ad011e988964a, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Thu Jun 23 05:02:13 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073998, encodeId=2afd10e39982a, content=还行。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b21989170, createdName=1e19ea9dm99(暂无匿称), createdTime=Thu Nov 25 22:12:14 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263683, encodeId=ef8812636833d, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342924, encodeId=f2cd13429242b, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377215, encodeId=9a0c13e7215e7, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072579, encodeId=37a310e257974, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe1f2374173, createdName=122fcb19m83暂无昵称, createdTime=Sun Nov 21 18:25:44 CST 2021, time=2021-11-21, status=1, ipAttribution=)]
    2021-11-22 bnurmamat
  4. [GetPortalCommentsPageByObjectIdResponse(id=1798896, encodeId=ad011e988964a, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Thu Jun 23 05:02:13 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073998, encodeId=2afd10e39982a, content=还行。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b21989170, createdName=1e19ea9dm99(暂无匿称), createdTime=Thu Nov 25 22:12:14 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263683, encodeId=ef8812636833d, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342924, encodeId=f2cd13429242b, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377215, encodeId=9a0c13e7215e7, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072579, encodeId=37a310e257974, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe1f2374173, createdName=122fcb19m83暂无昵称, createdTime=Sun Nov 21 18:25:44 CST 2021, time=2021-11-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1798896, encodeId=ad011e988964a, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Thu Jun 23 05:02:13 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073998, encodeId=2afd10e39982a, content=还行。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b21989170, createdName=1e19ea9dm99(暂无匿称), createdTime=Thu Nov 25 22:12:14 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263683, encodeId=ef8812636833d, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342924, encodeId=f2cd13429242b, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377215, encodeId=9a0c13e7215e7, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072579, encodeId=37a310e257974, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe1f2374173, createdName=122fcb19m83暂无昵称, createdTime=Sun Nov 21 18:25:44 CST 2021, time=2021-11-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1798896, encodeId=ad011e988964a, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Thu Jun 23 05:02:13 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073998, encodeId=2afd10e39982a, content=还行。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b21989170, createdName=1e19ea9dm99(暂无匿称), createdTime=Thu Nov 25 22:12:14 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263683, encodeId=ef8812636833d, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342924, encodeId=f2cd13429242b, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377215, encodeId=9a0c13e7215e7, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Mon Nov 22 05:02:13 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072579, encodeId=37a310e257974, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe1f2374173, createdName=122fcb19m83暂无昵称, createdTime=Sun Nov 21 18:25:44 CST 2021, time=2021-11-21, status=1, ipAttribution=)]
    2021-11-21 122fcb19m83暂无昵称

    学习了

    0

相关资讯

Oncogene:Plectin是前列腺癌生长和转移的调节因子

前列腺癌每年造成3万多美国人死亡,主要归因于无法治愈的转移性疾病。

Sci Adv:癌细胞为了转移长出“手指”!高侵袭性肺癌前导细胞“手指”更长

肿瘤的异质性是恶性肿瘤的特征之一,是指肿瘤在生长过程中,经过多次分裂增殖,其子细胞呈现出分子生物学或基因方面的改变,从而使肿瘤的生长速度、侵袭能力、对药物的敏感性、预后等各方面产生差异。

BMC Neurosci:SCN11A基因缺失引起感音神经性听力损失

SCN11A基因编码了Nav1.9 TTX耐钠离子通道,是外周炎症相关痛觉神经元的主要效应器。SCN11A基因在听觉系统中的作用尚未很好的表征。

JNNP:肌萎缩侧索硬化症系统基因筛查的价值

肌萎缩侧索硬化症(ALS)是一种以运动皮质、脑干和脊髓上下运动神经元进行性损伤和细胞死亡为特征的成人神经退行性疾病。这导致神经肌肉系统进行性衰竭,大多数病例在症状出现后2-5年内死亡,通常死于呼吸衰竭

Nature:一种单一的设计性DNA药物治疗有望完全治愈帕金森症!

虽然大多数治疗策略旨在防止神经元丢失或保护脆弱的神经元回路,但近日,付向东团队成功替换丢失的神经元以重建中断的回路,完全治愈了小鼠的帕金森病。

Nat. Rev Neurosci:对435563人酒精使用问题进行全基因组meta分析,深入了解生物学以及与其他性状的关系

酗酒是世界范围内导致死亡和残疾的主要原因。虽然全基因组关联研究已经确定了PAU的危险基因,但这一特性的遗传结构尚未完全了解。